Dyne 制药

最新新闻

• 公司公告
  Walter Dyn: Special Statement on Non-Operating Fund Occupancy and Other Related Party Transactions for the Year 2025 of Shandong Walter Dyn Health Co., Ltd.
  SZSI · 2026/4/24
• 公司公告
  Walter Dyn: Measures for the Management of Market Capitalization of Shandong Walter Dyn Health Co., Ltd.
  SZSI · 2026/8/21
• 评级变动
  Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $45
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• Stifel Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $37
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $44 to $47
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  J.P. Morgan Downgrades Dyne Therapeutics(DYN.US) to Sell Rating, Announces Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $37
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  A Quick Look at Today's Ratings for Dyne Therapeutics(DYN.US), With a Forecast Between $26 to $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Baird Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $26
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $32
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $47
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  Jefferies Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 公司公告
  Walter Dyn: Compensation Management System for Directors and Senior Management of Shandong Walter Dyn Health Co., Ltd.
  SZSI · 2026/4/24
• 评级变动
  Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 公司公告
  Walter Dyn: Summary Table of Non-Operating Fund Occupancy and Other Related Party Transactions for the First Half of 2026, Shandong Walter Dyn Health Co., Ltd.
  SZSI · 2026/8/21
• 评级变动
  Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $36
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 公司公告
  Walter Dyn: 2025 Annual Internal Control Audit Report of Shandong Walter Dyn Health Co., Ltd.
  SZSI · 2026/4/24
• 评级变动
  H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/8/17

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。